Novel immunohistochemical markers in early diagnostics of prostate cancer (review)

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

At this time positron emission tomography (PET) in combination with computed tomography (CT) — PET/CT is the most promising imaging technique for tumor detection in prostate. Areas of metabolic abnormality on the PET imaging here can be perfectly correlated with anatomical localization on the CT images. The efficiency of this modality could be significantly increased using radiopharmaceuticals targeting specific tumor cells. Such immunohistochemical markers as PSMA, PSCA, GRPR, EpCAM and VEGF are considered to be targets for novel diagnostic imaging techniques and treatment of prostate cancer

全文:

受限制的访问

作者简介

Maxim Ribalov

St.-Petersburg State I. P. Pavlov Medical University

aspirant, Department of Urology

Salman Al-Shukri

St.-Petersburg State I. P. Pavlov Medical University

Email: al-shukri@mail.ru
doctor of medical science, professor, head of the department of Urology

Sergey Borovets

St.-Petersburg State I. P. Pavlov Medical University

Email: sborovets@mail.ru
doctor of medical science, Department of Urology

参考

  1. Ananias H. J., van den Heuvel M. C., Helfrich W., de Jong I. J. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer // Prostate. 2009. Vol. 69, № 10. P. 1101–1108.
  2. Ananias H. J., de Jong I. J., Dierckx R. A. et al. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals // Curr Pharm Des. 2008. Vol. 14. P. 3033–3047.
  3. Benko G., Spajić B., Krušlin B, Tomas D. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer // Urol Oncol. 2011. Apr 20.
  4. Cornelio D. B., Roesler R., Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy//Ann Oncol. 2007. Vol.18, № 9. P.1457–1466.
  5. Ferrara N. Molecular and biological properties of vascular endothelial growth factor // J Mol Med (Berl). 1999. Vol. 77, № 7. P. 527–543.
  6. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress // Endocr Rev. 2004. Vol. 25, № 4. P. 581–611.
  7. Gu Z., Thomas G., Yamashiro J. et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer // Oncogene. 2000. Vol. 19, № 10. P. 1288–1296.
  8. Han K. R., Seligson D. B., Liu X. et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer // J Urol. 2004. Vol. 171, № 3. P. 1117–1121.
  9. Kaushal V., Mukunyadzi P., Dennis R. A. et al. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease // Clin Cancer Res. 2005. Vol. 11, № 2 Pt. 1. P. 584–593.
  10. Lam J. S., Yamashiro J., Shintaku I. P. et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases // Clin Cancer Res. 2005. Vol. 11, № 7. P. 2591–2596.
  11. Mukherjee S., Richardson A. M., Rodriguez-Canales J. et al. Identification of EpCAM as a molecular target of prostate cancer stroma // Am J Pathol. 2009. Vol. 175, № 6. P. 2277–2287.
  12. Munz M., Baeuerle P. A., Gires O. The emerging role of EpCAM in cancer and stem cell signaling // Cancer Res. 2009. Vol. 69. P. 5627–5629.
  13. Peyromaure M., Badoual C., Camparo P. et al. Plasma levels and expression of vascular endothelial growth factor-A in human localized prostate cancer // Oncol Rep. 2007. Vol. 18, № 1. P. 145–149.
  14. Reubi J. C., Körner M., Waser B. et al. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours // Eur J Nucl Med Mol Imaging. 2004. Vol. 31, № 6. P. 803–810.
  15. Ross S., Spencer S. D., Holcomb I. et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate // Cancer Res. 2002. Vol. 62, № 9. P. 2546–2553.
  16. Ross J. S., Sheehan C. E., Fisher H. A. et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer // Clin Cancer Res. 2003. Vol. 9, № 17. P. 6357–6362.
  17. Silver D. A., Pellicer I., Fair W. R. et al. Prostate-specific membrane antigen expression in normal and malignant human tissues // Clin Cancer Res. 1997. Vol. 3, № 1. P. 81–85.
  18. Troyer J. K., Beckett M. L., Wright G. L. Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids // Int J Cancer. 1995. Vol. 62, № 5. P. 552–558.
  19. Trzpis M., McLaughlin P. M., de Leij L. M., Harmsen M. C. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule // Am J Pathol. 2007. Vol. 171, № 2. P. 386–395.
  20. Zhigang Z., Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer // World J Surg Oncol. 2004. Vol. 10, № 2. P. 13.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Ribalov M.A., Al-Shukri S.K., Borovets S.Y., 2012

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 89281 от 21.04.2025.